S&P 500   3,841.47 (-0.30%)
DOW   30,996.98 (-0.57%)
QQQ   325.52 (-0.26%)
AAPL   139.38 (+1.83%)
MSFT   226.47 (+0.67%)
FB   275.01 (+0.78%)
GOOGL   1,892.50 (+0.44%)
AMZN   3,293.00 (-0.42%)
TSLA   845.61 (+0.07%)
NVDA   548.20 (-1.17%)
BABA   258.34 (-0.64%)
CGC   33.80 (+0.72%)
GE   11.15 (+0.72%)
MU   82.18 (-3.33%)
AMD   92.62 (+1.19%)
NIO   61.82 (+5.97%)
T   28.96 (+0.45%)
F   11.52 (-0.09%)
ACB   10.56 (-5.46%)
BA   206.11 (-0.63%)
DIS   172.75 (+0.86%)
NFLX   564.96 (-2.57%)
GILD   66.97 (-0.01%)
S&P 500   3,841.47 (-0.30%)
DOW   30,996.98 (-0.57%)
QQQ   325.52 (-0.26%)
AAPL   139.38 (+1.83%)
MSFT   226.47 (+0.67%)
FB   275.01 (+0.78%)
GOOGL   1,892.50 (+0.44%)
AMZN   3,293.00 (-0.42%)
TSLA   845.61 (+0.07%)
NVDA   548.20 (-1.17%)
BABA   258.34 (-0.64%)
CGC   33.80 (+0.72%)
GE   11.15 (+0.72%)
MU   82.18 (-3.33%)
AMD   92.62 (+1.19%)
NIO   61.82 (+5.97%)
T   28.96 (+0.45%)
F   11.52 (-0.09%)
ACB   10.56 (-5.46%)
BA   206.11 (-0.63%)
DIS   172.75 (+0.86%)
NFLX   564.96 (-2.57%)
GILD   66.97 (-0.01%)
S&P 500   3,841.47 (-0.30%)
DOW   30,996.98 (-0.57%)
QQQ   325.52 (-0.26%)
AAPL   139.38 (+1.83%)
MSFT   226.47 (+0.67%)
FB   275.01 (+0.78%)
GOOGL   1,892.50 (+0.44%)
AMZN   3,293.00 (-0.42%)
TSLA   845.61 (+0.07%)
NVDA   548.20 (-1.17%)
BABA   258.34 (-0.64%)
CGC   33.80 (+0.72%)
GE   11.15 (+0.72%)
MU   82.18 (-3.33%)
AMD   92.62 (+1.19%)
NIO   61.82 (+5.97%)
T   28.96 (+0.45%)
F   11.52 (-0.09%)
ACB   10.56 (-5.46%)
BA   206.11 (-0.63%)
DIS   172.75 (+0.86%)
NFLX   564.96 (-2.57%)
GILD   66.97 (-0.01%)
S&P 500   3,841.47 (-0.30%)
DOW   30,996.98 (-0.57%)
QQQ   325.52 (-0.26%)
AAPL   139.38 (+1.83%)
MSFT   226.47 (+0.67%)
FB   275.01 (+0.78%)
GOOGL   1,892.50 (+0.44%)
AMZN   3,293.00 (-0.42%)
TSLA   845.61 (+0.07%)
NVDA   548.20 (-1.17%)
BABA   258.34 (-0.64%)
CGC   33.80 (+0.72%)
GE   11.15 (+0.72%)
MU   82.18 (-3.33%)
AMD   92.62 (+1.19%)
NIO   61.82 (+5.97%)
T   28.96 (+0.45%)
F   11.52 (-0.09%)
ACB   10.56 (-5.46%)
BA   206.11 (-0.63%)
DIS   172.75 (+0.86%)
NFLX   564.96 (-2.57%)
GILD   66.97 (-0.01%)
Log in
NASDAQ:AXON

Axovant Sciences Stock Forecast, Price & News

$2.88
+0.01 (+0.35 %)
(As of 01/21/2021 12:00 AM ET)
Add
Compare
Today's Range
$2.75
Now: $2.88▼
$3.02
50-Day Range
$1.22
MA: $2.59▼
$3.19
52-Week Range
$0.93
Now: $2.88▼
$6.59
Volume1.51 million shs
Average Volume1.53 million shs
Market Capitalization$352.16 million
P/E RatioN/A
Dividend YieldN/A
Beta1.21
Sio Gene Therapies Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of gene therapies for neurological diseases. Its product pipeline focus on Parkinson's Disease, GM1 gangliosidosis, and GM2 gangliosidosis such as Tay-Sachs disease and Sandhoff disease. Axovant operates through seven wholly owned subsidiaries and also has business operations in Basel, Switzerland and New York, NY. The company was founded on October 31, 2014 and is headquartered in New York, NY.
Axovant Sciences logo

MarketRank™

Overall MarketRank™

0.61 out of 5 stars

Medical Sector

1300th out of 1,921 stocks

Pharmaceutical Preparations Industry

584th out of 769 stocks

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AXON
Previous Symbol
CUSIPN/A
CIK1636050
Webwww.axovant.com
Phone(877) 746-4891
EmployeesN/A

Debt

Debt-to-Equity Ratio1.24
Current Ratio2.02
Quick Ratio2.02

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.19 per share
Price / Book15.16

Profitability

EPS (Most Recent Fiscal Year)($2.06)
Net Income$-221,570,000.00
Net MarginsN/A
Return on Equity-416.05%
Return on Assets-124.55%

Miscellaneous

Outstanding Shares122,279,000
Market Cap$352.16 million
Next Earnings DateN/A
OptionableOptionable
$2.88
+0.01 (+0.35 %)
(As of 01/21/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AXON News and Ratings via Email

Sign-up to receive the latest news and ratings for AXON and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Axovant Sciences (NASDAQ:AXON) Frequently Asked Questions

How has Axovant Sciences' stock price been impacted by Coronavirus?

Axovant Sciences' stock was trading at $2.82 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AXON shares have increased by 2.1% and is now trading at $2.88.
View which stocks have been most impacted by COVID-19.

What stocks does MarketBeat like better than Axovant Sciences?

Wall Street analysts have given Axovant Sciences a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Axovant Sciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as Axovant Sciences' CEO?

1,448 employees have rated Axovant Sciences CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 60% among Axovant Sciences' employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

How were Axovant Sciences' earnings last quarter?

Axovant Sciences Ltd. (NASDAQ:AXON) announced its earnings results on Thursday, February, 7th. The biotechnology company reported ($0.27) EPS for the quarter, meeting analysts' consensus estimates of ($0.27).
View Axovant Sciences' earnings history.

Who are some of Axovant Sciences' key competitors?

Some companies that are related to Axovant Sciences include DiaMedica Therapeutics (DMCAF), Mersana Therapeutics (MRSN), Travere Therapeutics (RTRX), Travere Therapeutics (TVTX), Trillium Therapeutics (TRIL), Indivior (INVVY), Keros Therapeutics (KROS), Applied Molecular Transport (AMTI), MacroGenics (MGNX), Antibe Therapeutics (ATBPD), Antibe Therapeutics (ATBPD), Antibe Therapeutics (ATBPF), Innoviva (INVA), Frequency Therapeutics (FREQ) and Kiniksa Pharmaceuticals (KNSA).
View all of AXON's competitors.

What other stocks do shareholders of Axovant Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Axovant Sciences investors own include Novavax (NVAX), NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA), (CGC), Micron Technology (MU), TherapeuticsMD (TXMD), ACADIA Pharmaceuticals (ACAD), bluebird bio (BLUE) and Arena Pharmaceuticals (ARNA).

Who are Axovant Sciences' key executives?

Axovant Sciences' management team includes the following people:
  • Pavan Cheruvu, Chief Executive Officer & Director
  • David W. Nassif, Chief Financial & Accounting Officer
  • Gavin R. Corcoran, Chief Research & Development Officer
  • Raquel Crystal, Head-Human Resources & Vice President
  • Greg Stewart, Senior VP-Vector Delivery & Optimization

When did Axovant Sciences IPO?

(AXON) raised $251 million in an initial public offering on Thursday, June 11th 2015. The company issued 17,900,000 shares at $13.00-$15.00 per share. Jefferies, Evercore ISI and RBC Capital Markets acted as the underwriters for the IPO and JMP Securities and Baird were co-managers.

What is Axovant Sciences' stock symbol?

Axovant Sciences trades on the NASDAQ under the ticker symbol "AXON."

How do I buy shares of Axovant Sciences?

Shares of AXON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Axovant Sciences' stock price today?

One share of AXON stock can currently be purchased for approximately $2.88.

How big of a company is Axovant Sciences?

Axovant Sciences has a market capitalization of $352.16 million. The biotechnology company earns $-221,570,000.00 in net income (profit) each year or ($2.06) on an earnings per share basis.

What is Axovant Sciences' official website?

The official website for Axovant Sciences is www.axovant.com.

How can I contact Axovant Sciences?

Axovant Sciences' mailing address is 20-22 BEDFORD ROW, LONDON X0, WC1R 4JS. The biotechnology company can be reached via phone at (877) 746-4891.

This page was last updated on 1/22/2021 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.